ENTX - Entera Bio Ltd - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ENTX is currently covered by 1 analysts with an average price target of $7.95. This is a potential upside of $6.05 (318.42%) from yesterday's end of day stock price of $1.9.

Entera Bio Ltd's activity chart (see below) currently has 8 price targets and 12 ratings on display. The stock rating distribution of ENTX is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for ENTX is $10, Lowest price target is $10, average price target is $10.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 18-Mar-2025. First documented stock forecast 12-Mar-2021.

Best performing analysts who are covering ENTX - Entera Bio Ltd:

Kalpit Patel Jason Mccarthy Raghuram Selvaraju Nathan Weinstein

Currently out of the existing stock ratings of ENTX, 7 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)

Buy

$10

$8 (400.00%)

5 months 2 days ago
(18-Mar-2025)

0/4 (0%)

$8.05 (412.82%)

Please subscribe to see the analyst performance score

Kalpit Patel (B.RILEY)

Buy

$3 (150.00%)

3 years 1 months 1 days ago
(19-Jul-2022)

0/4 (0%)

$3.55 (244.83%)

Please subscribe to see the analyst performance score

Nathan Weinstein (CITI)

Buy

$12

$10.19 (562.98%)

$12

3 years 4 months 29 days ago
(22-Mar-2022)

0/2 (0%)

$9.5 (380.00%)

Please subscribe to see the analyst performance score

Jason Mccarthy (MAXIM GROUP)

Buy

$10

$9.17 (1104.82%)

4 years 5 months 9 days ago
(12-Mar-2021)

0/1 (0%)

$3.1 (44.93%)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is ENTX (Entera Bio Ltd) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on ENTX (Entera Bio Ltd) with a proven track record?

KALPIT PATEL

Which analyst has the current lower performing score on ENTX (Entera Bio Ltd) with a proven track record?

NATHAN WEINSTEIN

Which analyst has the most public recommendations on ENTX (Entera Bio Ltd)?

Kalpit Patel works at B. RILEY and has 3 price targets and 2 ratings on ENTX

Which analyst is the currently most bullish on ENTX (Entera Bio Ltd)?

Nathan Weinstein with highest potential upside - $10.19

Which analyst is the currently most reserved on ENTX (Entera Bio Ltd)?

Kalpit Patel with lowest potential downside - $3

Entera Bio Ltd in the News

Entera Bio Beats Q2 EPS Estimates

Key Points GAAP earnings per share of $0.06 in Q2 2025 beat analyst expectations by $0.17, despite higher research spending. No revenue was reported for the quarter, underscoring Entera Bio’s pre-commercial stage and continued reliance on capital reserves. Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles.These 10...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies and next-gen EB613 expected to enter Phase 1 in November 2025 Strong momentum across OPKO...